Molecular pathology laboratories need to provide prompt assessments of the molecular biomarkers present in tumor samples to allow informed treatment decisions. AuraSeq uses next-generation sequencing (NGS) technology enabling the testing of multiple biomarkers, such as somatic variants in oncogenic driver genes, in a single assay. 

For further information, please contact:

Jorge Almenara, Ph.D.
Strategic Accounts Manager
Acting General Manager for Bernhardt Laboratories
P: 804.551.1598

Info_apdivision@sonichealthcareusa.com

 

Brad Bernhardt
Director of Product Development
Anatomic Pathology Division, Sonic Healthcare USA
P: 904.813.3088

Info_apdivision@sonichealthcareusa.com

Reference:  Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998-2006.